

2024 RESEARCH FAST FACTS

Research Programs Overview



RESEARCH GRANT INVESTMENT AT A GLANCE: (1982-2024)

Nearly **\$1.1 billion** in over **2,830** research grants and more than **590** clinical trials

ABOUT OUR RESEARCH PROGRAMS

Despite successes in awareness and progress in diagnosis and treatment, breast cancer remains a devastating disease. Nearly 43,000 breast cancer deaths are predicted this year in the U.S. alone. Komen believes the future of breast cancer prevention, diagnosis, and treatment will come from breakthrough research focused on the most deadly and aggressive forms of breast cancer, including metastatic breast cancer (MBC), and by solving the causes of breast cancer health disparities. Our focus remains to advance precision medicine, improve health outcomes for everyone, and train the next generation of cancer researchers.

WHAT WE'RE INVESTIGATING



Investigating several vaccine and immunotherapy treatment approaches that target the body's own immune cells to help the body's immune system destroy breast cancer.



Studying new ways to treat metastatic breast cancer, including brain and bone metastasis.



[Assessing ways](#) to help doctors determine which Black women are at a higher risk of breast cancer so they can make more informed decisions about their health.

IN THE KOMEN RESEARCH PIPELINE:

More than **4,100** new breast cancer **research discoveries** (drugs, biomarkers, devices, etc.)

Nearly **1,500** new **discoveries** focused on **MBC & aggressive breast cancers.**



More than **1,800** **potential treatments**, more than **800** focused on **MBC & aggressive breast cancers.**



Nearly **600** new **strategies to reduce breast cancer disparities.**



SPOTLIGHT

Our research investments are guided by more than 50 leading scientists and advocates, including our [Scientific Advisory Board](#) and [Komen Scholars](#). As a global leader in the fight against breast cancer, we have funded research in 47 states and DC, and 24 different countries. Our commitment to the most promising, innovative, and meaningful breast cancer research will never waver.



WHAT WE'VE LEARNED FROM KOMEN-FUNDED RESEARCH

- A new tumor genomic test may help people with early-stage HER2+ breast cancers and their doctors make better treatment decisions
- A combination of immunotherapy drug, atezolizumab, and carboplatin chemotherapy may significantly improve survival of patients with metastatic TNBC.
- A tool that calculates a risk score tailored for Black women, based on multiple tumor genes, may help reduce disparities in this population when added routine health care decision-making tools.



[LEARN MORE ABOUT BREAST CANCER](#)

[MORE KOMEN-FUNDED RESEARCH STORIES](#)

[GET INVOLVED & SUPPORT RESEARCH](#)